Report on Psychedelics

We spoke with Dr. Erica Zelfand of Simba Health, a primary care physcian and an advisor to the Oregon Psilocybin Initiative (OPI) campaign. We discussed how OPI’s IP-34 successfully qualified for the ballot and the path head. We also got into why, as a health care provider, she supports the legalization of psychedelics.

In the RoP Briefing for the week of July 13th

Decriminalize DC One Step Closer to Ballot

Another Cannabis Company Looks for New Life In Psychedelics

Synthesis Institute Raises $2.75M

In the RoP Briefing for the week of July 6th:

Psychedelics are almost a sure thing for Oregon’s ballot

Beckley Psytech Raises £3M to develop psychedelic drugs

Doctors To Apply to Dose Themselves with Psilocybin

Mindset Pharma prepares for go-public transaction

We spoke with Jos Schmitt, President and CEO of the NEO Exchange. Our conversation, which took place over a live webinar, covered how psychedelic ventures can set themselves up to effectively raise money and go public properly, we also discussed how investors can properly assess psychedelic opportunities.

In the RoP Briefing for the week of June 29th:

Majority of Canadians Support Some Access to Psilocybin

US Military Invests in Psychedelic Research

Psyc Firms Embrace Tech For Personalized Treatment

We spoke with Will Krawszik of Opportune Therapeutics about using machine learning to advance the development of psychedelic drugs.

In the RoP Briefing for the week of June 22nd:

Field Trip Charts Course Towards Public Market

Colorado Activists Eye Legalization Ballot Measure

New Wave Holdings Adds To Team

MindMed, NeonMind Add DMT to Portfolios

We spoke with Spencer Hawkswell of Therapsil about his organization's effort to gain psychedelic exemptions for terminally ill patients.

In This Week’s Briefing

Decriminalize Nature Launches Canadian Campaign

MindMed Announces New Targets in Pipeline

Champignon Closes Financing

Numinus Receives Key License Amendment

We spoke with Trevor Millar the Chair of MAPS Canada and Executive Director of the newly formed Canadian Psychedelic Association. We discuss Trevor’s work with ibogaine, what drew him to psychedelics and the work he’s doing as part of MAPS and CPA to increase psychedelic access in Canada.